American Society of Clinical Oncology annual meeting 2015

Zurück zum Zitat Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (Checkmate 017) of nivolumab (NIVO; anti-programmed death 1 (PD-1)) vs docetaxel (DOC) in previously treated advanced or metastaic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. (suppl;abstr 8009). Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (Checkmate 017) of nivolumab (NIVO; anti-programmed death 1 (PD-1)) vs docetaxel (DOC) in previously treated advanced or metastaic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33. (suppl;abstr 8009).

Zurück zum Zitat Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43.PubMedCrossRef Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43.PubMedCrossRef

Zurück zum Zitat Ellis P, Barrios CH, Eiermann W, et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J Clin Oncol. 2015;33. (suppl; abstr 507). Ellis P, Barrios CH, Eiermann W, et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J Clin Oncol. 2015;33. (suppl; abstr 507).

Zurück zum Zitat Bang YJ, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33. (suppl; abstr 4001). Bang YJ, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33. (suppl; abstr 4001).

Zurück zum Zitat Cunningham D, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 2015;33. (suppl; abstr 4000). Cunningham D, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 2015;33. (suppl; abstr 4000).

Zurück zum Zitat Pavlakis N, et al. INTEGRATE. A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. J Clin Oncol. 2015;33. (suppl 3; abstr 9). Pavlakis N, et al. INTEGRATE. A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. J Clin Oncol. 2015;33. (suppl 3; abstr 9).

Zurück zum Zitat Tapp WD. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). J Clin Oncol. 2015;33. (suppl; abstr 10501). Tapp WD. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). J Clin Oncol. 2015;33. (suppl; abstr 10501).

Zurück zum Zitat Mir O. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.,). J Clin Oncol. 2015;33. (suppl; abstr 10504). Mir O. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.,). J Clin Oncol. 2015;33. (suppl; abstr 10504).

Zurück zum Zitat Kim C. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma). J Clin Oncol. 2015;33. (suppl; abstr 10565). Kim C. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma). J Clin Oncol. 2015;33. (suppl; abstr 10565).

Zurück zum Zitat Burgess MA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.,). J Clin Oncol. 2015;33. (suppl; abstr TPS10578). Burgess MA. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.,). J Clin Oncol. 2015;33. (suppl; abstr TPS10578).

Zurück zum Zitat Demetri GD. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). J Clin Oncol. 2015;33. (suppl; abstr 10503). Demetri GD. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). J Clin Oncol. 2015;33. (suppl; abstr 10503).

Zurück zum Zitat Schoeffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).). J Clin Oncol. 2015;33. (suppl; abstr 10542). Schoeffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).). J Clin Oncol. 2015;33. (suppl; abstr 10542).

Zurück zum Zitat Joensuu H. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial). J Clin Oncol. 2015;33. (suppl; abstr 10505). Joensuu H. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial). J Clin Oncol. 2015;33. (suppl; abstr 10505).

Zurück zum Zitat Chandrajit PR. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.,). J Clin Oncol. 2015;33. (suppl; abstr 10537). Chandrajit PR. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.,). J Clin Oncol. 2015;33. (suppl; abstr 10537).

Zurück zum Zitat Blay JY. Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).). J Clin Oncol. 2015;33. (suppl; abstr 10506). Blay JY. Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).). J Clin Oncol. 2015;33. (suppl; abstr 10506).

Zurück zum Zitat Le DTL, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33. (suppl; abstr LBA 100). Late Breaking Abstract 100. Le DTL, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33. (suppl; abstr LBA 100). Late Breaking Abstract 100.

Zurück zum Zitat Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.). J Clin Oncol. 2015;33. (suppl; abstr 3508). Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.). J Clin Oncol. 2015;33. (suppl; abstr 3508).

Zurück zum Zitat Ruers T, Punt CJA, van Coevorden F, et al. Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).). J Clin Oncol. 2015;33. (suppl; abstr 3501). Ruers T, Punt CJA, van Coevorden F, et al. Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).). J Clin Oncol. 2015;33. (suppl; abstr 3501).

Zurück zum Zitat Gibbs P, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 ± selective internal radiation therapy ± bevacizumab in patients with metastatic colorectal cancer.). J Clin Oncol. 2015;33. (suppl; abstr 3502). Gibbs P, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 ± selective internal radiation therapy ± bevacizumab in patients with metastatic colorectal cancer.). J Clin Oncol. 2015;33. (suppl; abstr 3502).